Sort by
Refine Your Search
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
on the design, development, and realization of future communications technologies. You will be part of the team and contribute to ongoing developments in theory, algorithms and translation to practice in
-
suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers
-
validated approach to treating diseases at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues
-
at Takeda provides medical support across the asset lifecycle, from early clinical development to marketed products, in three areas, Gastrointestinal and Inflammation, Neuroscience, and Rare Genetics
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
approach to treating diseases at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn
-
to treating diseases at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific
-
-spectrum approach, we are committed to making CRISPR-based medicines a reality for people suffering from genetic diseases and to creating novel engineered cell therapies for various rare diseases
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA